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Abstract Lapatinib adds to the efficacy of trastuzumab in
preclinical models and also in the neo-adjuvant setting.
This study assesses the safety and feasibility of adding
lapatinib to paclitaxel and trastuzumab (THL) as part of the
adjuvant therapy for HER2-positive breast cancer (HER2?
BC). In this single-arm phase II study, patients with stages
I–III HER2? BC received standard anthracycline-based
chemotherapy followed by weekly taxane, with concurrent
standard trastuzumab, plus daily lapatinib for a total of
12 months. The primary endpoint was symptomatic con-
gestive heart failure, secondary endpoints included overall
safety. A total of 109 eligible patients were enrolled.
Median follow-up is 4.3 years. No patients experienced
congestive heart failure while on treatment. Mean left
ventricular ejection fraction at baseline and at the end of
THL were 63.6 % (N = 109, SD = 5.7) and 59.8 %
(N = 98, SD = 8.1), respectively [mean change -3.95 %
(N = 98, SD = 8.3), p \ 0.001]. One hundred and two
patients initiated post-AC treatment; of them, 31 % expe-
rienced grade 3 (no G4) diarrhea with lapatinib at 750 mg/
day. The addition of lapatinib to paclitaxel and trastuzumab
following AC does not add cardiac toxicity. Lapatinib dose
of 750 mg/day in combination with standard chemotherapy
plus trastuzumab has acceptable overall tolerability.
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Introduction
The human epidermal growth factor type 2 (HER2) is a
trans-membrane receptor with intrinsic tyrosine kinase
activity [1]. Approximately 15–20 % of invasive breast
cancers are HER2 positive by gene amplification or protein
overexpression [1–4]. The up-regulation of this pathway
conveys an increased risk for disease relapse, disease
progression, death [5], and an increased relative resistance
to various anticancer therapies [6, 7].
Trastuzumab is a recombinant humanized monoclonal
antibody against the extracellular domain of HER2 [8]. The
addition of trastuzumab to adjuvant chemotherapy regimens
of patients with early stage HER2? BC leads to a significant
improvement in disease-free survival (DFS) and overall
survival (OS) as compared with chemotherapy alone [8–12].
However, despite the use of adjuvant trastuzumab plus
chemotherapy [8, 13, 14], there is still a risk of relapse of
approximately 25 % at 5 years. Thus, the search to improve
the outcome of these patients continues [15].
Lapatinib is an oral dual HER1 (EGFR: epidermal
growth factor receptor) and HER2 tyrosine kinase inhibitor
targeting the intracellular domains of these receptors [16].
Lapatinib is currently approved by regulation agencies in
different parts of the world for the treatment of HER2?
metastatic breast cancer (MBC) in combination with che-
motherapy (capecitabine) or with endocrine therapy (le-
trozole) [17]. The different mechanisms of action of
lapatinib and trastuzumab against the HER2 receptor lead
to synergism of this combination in HER2 overexpressing
breast cancer cells, in both the metastatic and the neo-
adjuvant settings [18–21]. Consequently, the combination
of lapatinib and trastuzumab may lead to improved out-
comes as adjuvant therapy for patients with early stage
HER2? BC. This combination strategy is currently being
evaluated in the ALTTO (Adjuvant Lapatinib And/Or
Trastuzumab Treatment Optimisation) trial [22, 23].
Cardiotoxicity is an uncommon, but important side
effect of anti-HER2 therapy. Although the exact patho-
physiologic mechanism is not fully understood, the
mechanism appears more distinct than the one caused by
the anthracyclines or other anticancer agents [24, 25]. The
four largest adjuvant trastuzumab-based trials (N9831,
NSABP B-31, HERA, and BCIRG-006) have demonstrated
an incidence of asymptomatic decrease in LVEF between
7.4 and 17.3 %, with an incidence of severe heart failure
(New York Heart Association (NYHA) class III/IV) rang-
ing from 0.6 to 4.1 % [9–11]. Lapatinib-related cardiac
events appear to occur at a much lower rate (1.6 %), even
in patients previously treated with anthracyclines and
trastuzumab [26]. The RC0639 study reported herein is a
multicenter single-arm phase II clinical trial designed to
assess the cardiac safety and feasibility of the addition of
lapatinib to the standard adjuvant chemotherapy plus con-
current trastuzumab regimen similarly as provided on Arm
C of the N9831 clinical trial [8, 10, 15]. Of note is that
while we were conducting this pilot trial, there was another
pilot study conducted by Dang et al. [27]. Our manuscript
herein provides longer follow-up data and serves to put our
results in the context of the data by Dang et al. [27] and the
upcoming results of the large phase III ALTTO study.
Patients and methods
Patient eligibility
Eligible patients had centrally confirmed HER2-positive,
surgically resected, invasive breast cancer. HER2 status
was determined by an immunohistochemistry (IHC) score
of 3? (by Dako HercepTest FDA approved guideline) or
by the presence of gene amplification as determined by
fluorescence in situ hybridization (FISH) defined by a ratio
of greater than or equal to 2.0. This was reviewed at two
laboratories (Mayo Clinic, Rochester, MN and Scottsdale
AZ). A LVEF greater than or equal to 50 % measured by
multiple-gated acquisition (MUGA) scan or echocardio-
gram (ECHO) within 14 days of study entry was manda-
tory. Other selected eligibility requirements included age
(patients must be at least 18 years of age), Eastern Coop-
erative Oncology Group (ECOG) performance status less
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than or equal to two, and adequate hematologic, hepatic,
and renal function. Patients with myocardial infarction
within 6 months prior to registration, active angina pecto-
ris, history of congestive heart failure (CHF), uncontrolled
hypertension, or other clinically significant cardiac disease
were ineligible. Patients with gastrointestinal problems that
might interfere with the absorption of lapatinib were also
excluded. An Institutional Review Board approval and
patient informed consents were obtained from all patients.
Study design and treatment
The primary endpoint of this trial (RC0639) was cardiac
safety, defined as the proportion of patients experiencing
severe symptomatic CHF (NYHA Class III or IV with a
drop in LVEF of at least 10 percentage points to below
50 % as confirmed by a cardiologist). Secondary endpoints
included overall safety profile, disease-free survival and
overall survival, and selected quality of life (QOL)
response by questionnaire. Tertiary endpoints included
translational biomarkers.
The treatment schedule consisted of four cycles of
doxorubicin (A: 60 mg/m2 day 1) and cyclophosphamide
(C: 600 mg/m2 day 1) every 2 or 3 weeks, with or without
the use of pegylated-G-CSF, followed by 12 weeks of
THL: paclitaxel (T: 80 mg/m2 weekly), trastuzumab (H:
4 mg/kg loading dose on week one followed by 2 mg/kg
weekly), and lapatinib (L: 1,000 mg PO daily), followed by
40 weeks of HL: trastuzumab (6 mg/kg day 1, every
3 weeks) and L: lapatinib (1,000 mg orally daily). The
study was amended in July 2008, reducing the dose of L
when given concurrently with T and H (from 1,000 to
750 mg/day) because of the high incidence of grade 3 and/
or 4 (G3/4) diarrhea observed in the ongoing study.
Patients received radiation and adjuvant endocrine
therapy according to standard treatment guidelines based
on prior surgical approach, stage, and tumor characteristics.
Toxicity evaluation
The adverse effects were graded according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. Initiation of THL
was not allowed in patients who developed significant
cardiac events while receiving AC, or in asymptomatic
patients with a significant decrease in the LVEF (greater
than or equal to 16 % from baseline or less than or equal to
15 % but with an LVEF less than 50 %), upon completion
of AC. Evaluation of LVEF was done within 14 days
before registration, at the end of Cycles 4, 8, and 12, and at
18 months, then again at 2, 3, 4, and 5 years post-
randomization.
Treatment dose modifications
Treatment dose modification algorithms were designed for
the management of cardiac toxicity and diarrhea (Figs. 1,
2). T and L were permanently discontinued if the patient
had a LVEF decrease of 10 % or more plus a LVEF less
than 40 %. If LVEF was between 40 and 49 %, we omitted
the dose and re-evaluated LVEF in 3 weeks. If LVEF was
less than or equal to 50 % or between 45 and 49 % with a
decrease less than 10 % of baseline, then the patient con-
tinued T (without dose modification) and L (with
Fig. 1 Algorithm for the management of cardiac toxicity in RC0639
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consideration of dose reduction). If LVEF remained less
than 50 % and it represented a decrease of 10 % or more
from baseline value, T and L were stopped permanently.
One dose reduction in lapatinib (from 1,000 to 750 mg/
day during HL or from 750 to 500 mg/day during THL
after the mentioned amendment) was also permitted for
other G3/4 lapatinib-related AE. Treatment could be
delayed for at least 3 weeks to allow for resolution of the
AE. If treatment had to be delayed for more than 3 weeks,
then patients were taken off the study. In case of G3/4
confirmed interstitial pneumonitis, lapatinib was to be
discontinued permanently. Management of treatment-rela-
ted diarrhea is outlined in Fig. 2.
Statistical considerations
The primary endpoint of this trial was the proportion of
patients experiencing CHF during the first 6 months of
treatment. A true CHF rate of 3.5 % or less was considered
acceptable, and a true CHF rate of 10 % or more would be
unacceptably high. A two-stage design called for the
treatment of 42 eligible patients in the first stage and a total
of 101 eligible patients treated to test the null hypothesis
that the true CHF rate in the given patient population was
at most 3.5 %.
Statistical results presented herein primarily include
descriptive statistics. Additionally, disease-free survival
was defined as time from registration to first breast cancer
recurrence, new primary cancer or death due to any cause.
Overall survival was defined as time from registration to
death due to any cause. Disease-free survival and overall
survival were estimated using Kaplan–Meier. Post-baseline
LVEF was compared to baseline using paired t tests.
Results
Patient baseline characteristics
From April 2007 to October 2008, 122 patients were
enrolled. Median follow-up was 4.3 years (range 0.1–5.2).
Ten patients were deemed ineligible due to uncorroborated
HER2 positivity (by the central laboratory evaluation), one
patient withdrew prior to treatment, one patient withdrew
after beginning treatment, and one patient had a major
treatment violation.
Characteristics of the remaining 109 patients are out-
lined in Table 1. The median age was 51.2 (28–72) years,
and 53.2 % were postmenopausal at the time of registra-
tion. Fifty-five percent of patients had node-positive dis-
ease, and 50.5 % of patients had ER-/PR-negative tumors.
Mastectomy and radiation therapy was performed in 65
patients (59.6 %). Most patients (78.9 %) received AC
therapy in a dose-dense fashion.
Table 2 outlines reasons for ending active treatment.
Twenty-three percent were due to treatment-related AEs,
Fig. 2 Algorithm for the management of diarrhea in RC0639
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mainly before the protocol amendment in May 2008 due to
the higher than expected incidence of G3/4 diarrhea in the
first 68 eligible patients treated with THL.
Cardiac safety and cardiac events
No patients experienced CHF or cardiac death while on
active treatment. However, there was one patient with
confirmed CHF, and one patient who may have died due to
myocardial infarction (MI) after they went off the study
treatment. The patient with CHF experienced grade 1 left
ventricular systolic dysfunction in Cycle 4 and G1 diastolic
dysfunction in Cycles 4 and 6 and refused further treatment
after completing 2 cycles of THL. Clinically symptomatic
CHF occurred 1.8 months post-THL discontinuation with
an LVEF of 45 % and dyspnea on exertion. The patient
received an angiotensin converting enzyme (ACE) inhibi-
tor, a beta blocker and a diuretic for ongoing management
of CHF for the next 2 years. One year after the confirmed
CHF episode, this patient was reported to be asymptomatic
with an LVEF of 59 %. Two years after the confirmed CHF
event, the patient’s LVEF was 60 % and the patient was
reported to be asymptomatic and taking no medications.
The other patient who sustained a cardiac event went off
study treatment due to G3 diarrhea and died suddenly
2.9 months post-discontinuation of therapy. It was pre-
sumed by the local physician that the event was related to a
massive MI, although an autopsy was not performed.
Because in these two patients the cardiac events occurred
up to 3 months after coming off study, it seems warranted
to continue monitoring cardiac symptoms for a few months
upon discontinuation of dual anti-HER2 therapy.
Five patients (4.6 %) had other G3/4 cardiac adverse
events (CAEs) during active treatment, three (2.8 %) pre-
sented with G3 left ventricular dysfunction, and two
(1.8 %) with G4 thrombosis. Regarding the three patients
with G3 left ventricular failure, one patient’s reported that
LVEF remained less than 50 % for 12 months and recov-
ered after 18 months with three LVEF reports of over 50 %
each 1 year apart. Another patient had continued LVEF
reports less than 50 % 2 years after discontinuing treat-
ment, and the other patient recovered to have an LVEF
Table 1 Patient baseline characteristics (N = 109)
Characteristic No. of patients %
Median age, years (range) 51 (Range 28–72)
Race
White 94 86.2
Black or African-American 12 11
Asian 2 1.8














SLN? without full axillary dissection 2 1.8
Hormonal status
ER and/or PR positive 54 49.5
ER and PR negative 55 50.5
HER2 status
Positive 109 100
FISH Amp/IHC Pos 93 85.3
FISH Amp/IHC Neg 8 7.3
FISH Not Amp/IHC Pos 6 5.5
FISH not done/IHC Pos 2 1.8




Data not available 25 22.9










ECOG PS Eastern Cooperative Oncology Group performance status
Table 2 Reasons for ending active treatment
Completed study per protocol 55 (50.5 %)
Refused further treatment 20 (18.3 %)
• Unacceptable side effects 9 (8.3 %)
• Reason not given 7 (6.4 %)
• Non-compliant 2 (1.8 %)
• Patient choice 2 (1.8 %)
Adverse event 25 (22.9 %)
Disease progression 1 (0.9 %)
Alternate treatment 1 (0.9 %)
Other medical problems 2 (1.8 %)
Other 5 (4.6 %)
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over 50 % 3 months after discontinuing treatment, but had
the LVEF drop to less than 50 % 8 months later. Table 3
summarizes all CAEs.
Serial evaluation of LVEF
Table 4 shows mean and median values and ranges of
LVEF for each evaluation point and the absolute LVEF
changes from baseline evaluation. Statistically significant
decreases from baseline in the LVEF were observed at the
Cycle 8, Cycle 12, 18 months and 5-year evaluation points.
Despite the statistical significance at some evaluation
points, the mean changes were less than 5 % from baseline
and therefore not clinically significant in most cases.
Adverse event profile
Considering all AEs from Cycle 1 and later, the most
common AEs were fatigue (94 %), diarrhea (91 %),
neuropathy-sensory effects (70 %), acneiform rash (61 %),
myalgia (59 %), arthralgias (61 %), bone pain (54 %), and
decrease in LVEF (53 %; G1/2: 50 %). Diarrhea was, by
far, the most common G3/4 AE (38 %). Due to the high
incidence of diarrhea G3/4 during the early accrual, the
study was amended reducing the dose of lapatinib when
given concurrently with paclitaxel (dose reduced from
1,000 to 750 mg/day for Cycles 5–8, that is, THL;
1,000 mg/day dosing was resumed after treatment with
paclitaxel had ended). This dose reduction, along with a
more aggressive and early treatment of the diarrhea, as
outlined in Fig. 2, allowed for an improvement in the
incidence of G3/4 diarrhea events, which led to an
increased number of patients being able to receive lapatinib
concomitantly with trastuzumab and paclitaxel during
Cycles 5–8. Among patients initiating THL at the
1,000 mg/day lapatinib dose, G3 diarrhea following THL
initiation was 41 % (30/73) and G4 2.7 % (2/73); and at the
750 mg/day lapatinib dose, G3 was 31 % (9/29) and no G4
was reported. Mild liver transaminitis were common (22
and 23 % G1/2 increase in AST/ALT, respectively), but
severe abnormalities of these liver enzymes were rare (G3/
4 \ 3 %). Leukopenia/neutropenia were the most common
hematologic AEs (G3/4 occurring with a frequency of 22.9
and 27.5 %, respectively). Table 5 summarizes all the AEs
occurring with an incidence of 20 % or more.
Disease-free survival and overall survival
Five patients experienced disease recurrence, and one
patient developed a new primary cancer. At last follow-up,
five patients had died (four due to breast cancer and one
due to suspected MI). Disease-free survival at 3 years was
estimated to be 92.9 % (95 % CI 85.6–96.5). Overall sur-
vival at 3 years was estimated to be 95.0 % (95 % CI
88.4–97.9).
Table 3 All cardiac adverse events
Cardiac adverse event All treatment Post-AC
G1 left ventricular failure 45 (41.3 %) 41 (40.2 %)
G2 left ventricular failure 10 (9.2 %) 9 (8.8 %)
G3 left ventricular failure 3 (2.8 %) 3 (2.9 %)
G1 diastolic dysfunction 10 (9.2 %) 10 (9.8 %)
G2 diastolic dysfunction 1 (0.9 %) 1 (1.0 %)
G2 hypotension 1 (0.9 %) 1 (1.0 %)
G4 thrombosis 2 (1.8 %) 2 (1.8 %)
All treatment: N = 109; Post-AC: N = 102
CTCAE v3.0: left ventricular failure G1 = \60–50 %,
G2 = \50–40 %, G3 = \40–20 % and symptomatic CHF respon-
sive to intervention; Diastolic dysfunction: G1 = Asymptomatic,
intervention not indicated, G2 = Asymptomatic, intervention
indicated
Table 4 LVEF for each evaluation point
Visit N Mean (%) SD (%) Median (%) Range (%) LVEF absolute changes from baseline
Mean (%) SD (%) p* Median (%) Range (%)
Baseline 109 63.6 5.7 63.3 52–78
End cycle 4 105 63.3 6.4 63 48.5–78 -0.58 5.6 0.29 0 -15–16
Cycle 8 98 59.8 8.1 60 20–77 -3.95 8.3 \0.001 -2.6 -32–22
Cycle 12 95 59.3 7.1 60 41–79 -4.45 7.2 \0.001 -5 -26–13
18 Months 87 60.1 6.8 60 45–86 -3.51 6.9 \0.001 -4.5 -16.4–15
2 Years 71 62.1 7.4 62 43–84 -1.67 7.6 0.07 -1.2 -24.7 – 14.2
3 Years 61 61.5 7.4 61 30–80 -2.05 8.5 0.06 -2 -32.1–15
4 Years 51 61.6 6.6 62 35–75 -2.01 7.7 0.07 -1 -20–15
5 Years 20 57.7 6.9 58.1 40–68 -4.83 9.2 0.03 -3.5 -30–12
SD standard deviation
* Paired t test p value
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Discussion
Despite the significant benefit of the addition of trast-
uzumab for the adjuvant treatment of HER2? BC, up to
one out of every four patients still relapses at 5 years [8–
12]. The current data of the activity of single agent lapat-
inib in combination with chemotherapy in the adjuvant or
neo-adjuvant setting of patients with early stage HER2?
BC seem to be no better and in some trials even inferior to
trastuzumab and chemotherapy [28]. Additionally, the
HER2? subset of patients (n = 620) in the German neo-
adjuvant phase III GeparQuinto trial, who received four
cycles of epirubicin and cyclophosphamide followed by
four cycles of docetaxel along with standard dose of
trastuzumab (n = 307) or lapatinib (n = 308) at 1,000 mg/
daily during the entire length of the chemotherapy regimen
(24 weeks), were also noted to achieve a lower patholog-
ical complete response (pCR) with lapatinib (22.7 %) than
with trastuzumab (30.3 %; p = 0.04) [29]. However, sev-
eral sources of preclinical and clinical data suggest that
combined anti-HER2 approaches may be optimal for effi-
cacy. The dual HER2 blockade seems to significantly
improve the pCR rate of patients receiving this combina-
tion in the neo-adjuvant setting, and achieving a pCR in
patients with HER2 ? disease is associated with improved
long-term outcome [21, 29]. The neo-adjuvant neo-ALTTO
trial randomized 455 patients who received either lapatinib
or trastuzumab, or lapatinib with trastuzumab for a total of
6 weeks. Patients then continued on the same targeted
therapy plus weekly paclitaxel for a further 12 weeks until
surgery. This demonstrated that the combination led to a
51.3 % pCR rate compared with either trastuzumab or la-
patinib alone (29.5 % vs. 24.7 %, respectively; p \ 0.01
for both) [19], corroborating that dual blockade is more
effective than a single anti-HER2 agent alone.
Our study evaluated the cardiac safety of the addition of
lapatinib to the standard chemotherapy plus trastuzumab
regimen provided in arm C of the N9831 pivotal trial [8,
10]. The 3-year cumulative incidence of cardiac events
(AE or cardiac deaths) observed in the N9831 adjuvant
treatment regimen was 3.3 % [26]. In the current RC0639
clinical trial, no cases of symptomatic CHF were noted
during on-study treatment and only 3 % of the patients
were classified as having grade 3 decrease in LVEF (EF
20–40 %). The incidence of CHF noted in this trial is
actually numerically lower than that reported in a smaller
phase II trial of dose-dense AC therapy followed by THL
reported by Dang et al. [27]. In the Dang et al. trial, the
chemotherapy and trastuzumab doses were similar to our
study, and lapatinib was given at 1,000 mg orally daily, for
up to 12 months along with trastuzumab. Median follow-
up was 22 months (range 18–31 months). Three out of 95
patients (3 %) in this study developed congestive heart
failure, and three patients dropped out because of signifi-
cant asymptomatic LVEF decline during THL followed by
HL. An additional three patients had a significant asymp-
tomatic LVEF decline but were subsequently able to
resume anti-HER2 therapy. The conclusion of the authors
was that this combination was not feasible, not because of
excessive cardiotoxicity, but due to excessive problems
with diarrhea (70 % of patients had diarrhea within the first
cycle of treatment, and the overall incidence of grade 3
diarrhea on the patients who received THL therapy was
29 %). Overall, 43 % of patients had a lapatinib dose
reduction, mostly because of grade 3 or unacceptable grade
2 or less diarrhea despite active management.
One of the limitations of our present study is that only
50.5 % of patients enrolled completed the entire treatment as
specified in the protocol, which could limit the evaluation of
cardiac toxicity. The main reasons for the high dropout rate
were patient refusal or intolerable AEs, particularly diarrhea,
as also noted by Dang et al. However, the subsequent dose
modification of lapatinib and early, aggressive management
of the diarrhea alleviated symptoms and allowed more
patients to adhere to the on-protocol treatment. Similar
findings were encountered in a 3-cohort phase I trial of 63
patients receiving the combination of THL. When lapatinib
was prescribed at 1,000 mg/day, the most frequently repor-
ted AEs for all cohorts was diarrhea (83 %), but this AE was
significantly improved with the reduction in the lapatinib
dose to 750 mg/day and early institution of loperamide
(grade 3 diarrhea improved from 62 to 20 %) [30].
Diarrhea seems to be a frequent and challenging toxicity
in regimens using the combination of lapatinib–paclitaxel
Table 5 Adverse events occurring with an incidence of 20 % or
more
Adverse event Grade 1–2 Grade 3 Grade 4
Fatigue 87 (79.9 %) 14 (12.8 %) 1 (0.9 %)
Diarrhea 58 (53.2 %) 39 (35.8 %) 2 (1.8 %)
Neuro-sensory 71 (65.1 %) 5 (4.6 %) 0 (0 %)
Acne 61 (55.9 %) 5 (4.6 %) 0 (0 %)
Myalgia 61 (55.9 %) 3 (2.8 %) 0 (0 %)
Arthralgia 64 (58.7 %) 2 (1.8 %) 0 (0 %)
Pain-bone 53 (48.6 %) 6 (4.6 %) 0 (0 %)
Decrease LVEF 55 (50.5 %) 3 (2.8 %) 0 (0 %)
Dyspnea 44 (40.7 %) 3 (2.8 %) 1 (0.9 %)
Neutropenia 7 (6.4 %) 8 (7.3 %) 22 (20.2 %)
Alopecia 36 (33 %) 0 (0 %) 0 (0 %)
Anemia 30 (27.5 %) 4 (3.7 %) 0 (0 %)
Nausea 27 (24.8 %) 7 (6.4 %) 0 (0 %)
Leukopenia 8 (7.3 %) 12 (11 %) 13 (11.9 %)
ALT 25 (22.9 %) 3 (2.8 %) 0 (0 %)
AST 24 (22.0 %) 2 (1.8 %) 0 (0 %)
N = 109, includes all cycles of treatment, including AC chemotherapy
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[31] and may be related to increased systemic exposure of
these drugs when given concurrently [31, 32].
The experience gained in this pilot study as well as in
the subsequent NCCTG N083E pilot study (adjuvant
docetaxel, carboplatin, trastuzumab, and lapatinib; TCHL)
was extremely helpful in defining the management algo-
rithm for Arm D of the large phase III adjuvant ALTTO
trial (chemotherapy plus trastuzumab plus lapatinib as
given in these 2 pilot trials—RC0639 and N083E). These
data helped with the decision to use a starting dose of
750 mg/day of lapatinib during the combination of a taxane
and the dual HER2 blockade as well as helped to better
define the need for aggressive intervention for the man-
agement of diarrhea. Another important observation of our
study is that the lapatinib dose can be further reduced to
500 mg/day during THL and increased to 1,000 mg/day
during the HL phase depending on tolerability.
Conclusion
In conclusion, our data suggest that lapatinib given concur-
rently with paclitaxel and trastuzumab does not add toxicity
to the cardiac safety profile of the standard AC-TH regimen,
that the dose of lapatinib with concurrent taxane and trast-
uzumab should not exceed 750 mg daily, that diarrhea is the
most common serious AE of this regimen and early aggres-
sive management of it is absolutely necessary, and that
monitoring of cardiac symptoms for a few months upon
discontinuation of dual anti-HER2 therapy is warranted.
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